Focusing on the US is paying off for New Zealand software business Biomatters, which is reporting a 50 percent increase in sales revenue for 2011.
The company says more than half this growth took place in the US after it recently opened offices there on both the east and west coasts.
Its flagship product, Geneious, is a bioinformatics platform that enables researchers to search, organise and analyse genomic data using a single desktop programme.
Geneious was cited in scientific research publications more than 800 times in 2011 – more than double the previous year – and is a registered trademark in the US, Europe, Singapore, Australia, Switzerland and New Zealand.
Biomatters is a privately held company and exports to 80-plus countries. It was recently placed in the Deloitte Fast 50 index of New Zealand’s fastest growing businesses for the second year running. At the end of last year Biomatters was also ranked among the top 10 “hot emerging companies” in the New Zealand Technology Investment Network’s annual survey of technology businesses.
Managing director Dr Brett Ammundsen said the company intended to grow its US team in 2012 and focus on a growing customer base in Europe.
“We also have a number of new product enhancements in our development pipeline.”